AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28836528 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with diode laser (gallium aluminum arsenide, 810 nm, 0.1 W)
Number of subjects: 40
Study 28836528 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study 26239948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric Citrate (FC)
Number of subjects: 441
Study 26239948 — intervention group
Group type: COMPARATOR
Intervention: Active Control (AC) (sevelamer carbonate and/or calcium acetate)
Number of subjects: 441
Study 23670096 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 910
Study 23670096 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 910
Study 20800897 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 14
Study 20800897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 19137506 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits from a project nurse or medical doctor (10 visits during the first 2 years after discharge)
Number of subjects: 249
Study 19137506 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits from a project nurse or medical doctor
Number of subjects: 249
Study 19137506 — intervention group
Group type: COMPARATOR
Intervention: Control group (no home visits)
Number of subjects: 249
Study 18219837 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine hydrochloride, 15 mg, twice daily for 8 days
Number of subjects: 393
Study 18219837 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine hydrochloride, 30 mg, twice daily for 8 days
Number of subjects: 393
Study 18219837 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily for 8 days
Number of subjects: 393
Study 14742305 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast 300 mg twice a day
Number of subjects: 15
Study 14742305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 11549425 — intervention group
Group type: COMPARATOR
Intervention: Observation only (A)
Number of subjects: 127
Study 11549425 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 450 mg/m2 plus levamisol (B)
Number of subjects: 127
Study 11549425 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 600 mg/m2 (C)
Number of subjects: 127
Study 11549425 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 127
Study 9559784 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream
Number of subjects: 279
Study 9559784 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% imiquimod cream
Number of subjects: 279
Study 9559784 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 279
Study 7942076 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg estradiol valerate
Number of subjects: 20
Study 7942076 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg micronized estradiol
Number of subjects: 20
Study 3365527 — intervention group
Group type: EXPERIMENTAL
Intervention: Orudis (simple ketoprofen)
Number of subjects: 0
Study 3365527 — intervention group
Group type: EXPERIMENTAL
Intervention: Oruvail (slow release ketoprofen)
Number of subjects: 0
Study 3365527 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 0
Study 31999314 — intervention group
Group type: EXPERIMENTAL
Intervention: R20EFV600
Number of subjects: 98
Study 31999314 — intervention group
Group type: EXPERIMENTAL
Intervention: R20EFV800
Number of subjects: 98
Study 31999314 — intervention group
Group type: COMPARATOR
Intervention: R10EFV600
Number of subjects: 98
Study 29324968 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) for 10 years (n = 2,406)
Number of subjects: 4790
Study 29324968 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE) for 10 years (n = 2,384)
Number of subjects: 4790
Study 29324968 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 4790
Study 29324968 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 4790
Study 27423422 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating miRNAs in cases (DF, DH, DC)
Number of subjects: 45
Study 27423422 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating miRNAs in DH or DC cases
Number of subjects: 45
Study 27423422 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating miRNAs in DC vs. DF cases
Number of subjects: 45
Study 27423422 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating miRNAs in DC vs. DH cases
Number of subjects: 45
Study 26125735 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐CRT + docetaxel (36 mg/m(2) once weekly for 6 weeks) + adjuvant chemotherapy
Number of subjects: 60
Study 26125735 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐CRT + docetaxel + adjuvant chemotherapy
Number of subjects: 60
Study 26125735 — intervention group
Group type: COMPARATOR
Intervention: Control group (3D‐CRT + adjuvant chemotherapy)
Number of subjects: 60
Study 24047455 — intervention group
Group type: EXPERIMENTAL
Intervention: Bracing (at least 18 hours per day)
Number of subjects: 242
Study 24047455 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 242
Study 24047455 — intervention group
Group type: EXPERIMENTAL
Intervention: Bracing (randomly assigned)
Number of subjects: 242
Study 24047455 — intervention group
Group type: COMPARATOR
Intervention: Observation (randomly assigned, control group)
Number of subjects: 242
Study 24047455 — intervention group
Group type: EXPERIMENTAL
Intervention: Bracing (hours of wear)
Number of subjects: 242
Study 20934206 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 3 years
Number of subjects: 78
Study 20934206 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 4 years
Number of subjects: 78
Study 20934206 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for 5 years
Number of subjects: 78
Study 20934206 — intervention group
Group type: COMPARATOR
Intervention: Control group (drug therapy alone)
Number of subjects: 78
Study 18081812 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper
Number of subjects: 60
Study 18081812 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtwo
Number of subjects: 60
Study 18081812 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐Endo
Number of subjects: 60
Study 18081812 — intervention group
Group type: COMPARATOR
Intervention: Hedström files
Number of subjects: 60
Study 16782921 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and estramustine (DE)
Number of subjects: 674
Study 16782921 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone and prednisone (MP)
Number of subjects: 674
Study 12677456 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation Therapy (EST)
Number of subjects: 22
Study 12677456 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback Therapy (BFT)
Number of subjects: 22
Study 10988013 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator antigen
Number of subjects: 207
Study 10988013 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte elastase
Number of subjects: 207
Study 10988013 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood viscosity
Number of subjects: 207
Study 9402662 — intervention group
Group type: EXPERIMENTAL
Intervention: Current therapeutic strategies for tachyarrhythmias following CABG
Number of subjects: 0
Study 9402662 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic tools for postoperative arrhythmias
Number of subjects: 0
Study 1416271 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia (CSEA)
Number of subjects: 63
Study 1416271 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 63
Study 3161213 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172 (800 and 3200 anti‐Xa units)
Number of subjects: 12
Study 3161213 — intervention group
Group type: COMPARATOR
Intervention: Heparin (5000 IU)
Number of subjects: 12
Study 3161213 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 10172 (34.4 anti‐Xa units/kg)
Number of subjects: 12
Study 3161213 — intervention group
Group type: COMPARATOR
Intervention: Heparin (34.4 anti‐Xa units/kg)
Number of subjects: 12
Study 30904428 — intervention group
Group type: EXPERIMENTAL
Intervention: Grouper iridovirus (GIV) challenge; LPS and poly (I:C) challenges; specific genes EcSYCA102, EcSYCA103, EcSYCA116, and EcSYCA118 were highly induced in the spleen after challenge.
Number of subjects: 0
Study 30904428 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS and poly (I:C) challenges; specific genes EcSYCA102, EcSYCA103, EcSYCA116, and EcSYCA118 were upregulated.
Number of subjects: 0
Study 29417366 — intervention group
Group type: EXPERIMENTAL
Intervention: BFHI steps 1-9
Number of subjects: 0
Study 29417366 — intervention group
Group type: EXPERIMENTAL
Intervention: BFHI steps 1-10
Number of subjects: 0
Study 29417366 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 26350474 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment for 12 weeks
Number of subjects: 80
Study 26350474 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (CT) for 12 weeks
Number of subjects: 80
Study 24836438 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid PCR‐based screening test for MRSA
Number of subjects: 2500
Study 24836438 — intervention group
Group type: COMPARATOR
Intervention: Control screening test by enrichment culture using chromogenic agar
Number of subjects: 2500
Study 22186969 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIC)
Number of subjects: 1610
Study 22186969 — intervention group
Group type: COMPARATOR
Intervention: Sham RIC
Number of subjects: 1610
Study 22186969 — intervention group
Group type: EXPERIMENTAL
Intervention: RIC
Number of subjects: 1610
Study 20670728 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous compression stockings or compression bandages
Number of subjects: 620
Study 20670728 — intervention group
Group type: COMPARATOR
Intervention: Control group (no venous compression)
Number of subjects: 620
Study 19093288 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser light (dual wavelength of 650+/‐20 nm and 915+/‐10 nm) and massage
Number of subjects: 102
Study 19093288 — intervention group
Group type: COMPARATOR
Intervention: Massage alone (control)
Number of subjects: 102
Study 19093288 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser light and massage
Number of subjects: 102
Study 15655382 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril 20 mg
Number of subjects: 32
Study 15655382 — intervention group
Group type: COMPARATOR
Intervention: telmisartan 80 mg
Number of subjects: 32
Study 11912269 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 (0.25 to 3.5 mg)
Number of subjects: 20
Study 10069195 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF
Number of subjects: 40
Study 8819181 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms)
Number of subjects: 16
Study 8819181 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms)
Number of subjects: 16
Study 8819181 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 micrograms)
Number of subjects: 16
Study 8819181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2105115 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 1 g intravenously plus metronidazole 500 mg intravenously preoperatively (Group 1)
Number of subjects: 943
Study 2105115 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime 1.5 g intravenously plus metronidazole 500 mg intravenously preoperatively, followed by cefuroxime 750 mg intravenously plus metronidazole 500 mg intravenously eight hours and 16 hours postoperatively (Group 2)
Number of subjects: 943
Study 2105115 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime plus metronidazole (Group 1)
Number of subjects: 943
Study 2105115 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime plus metronidazole (Group 2)
Number of subjects: 943
Study 2105115 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 943
Study 6446445 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid (1500 mg)
Number of subjects: 60
Study 6446445 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (3600 mg)
Number of subjects: 60
Study 6446445 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone (300 mg)
Number of subjects: 60
Study 6446445 — intervention group
Group type: COMPARATOR
Intervention: Dextropropoxyphene plus paracetamol (260 mg plus 2600 mg)
Number of subjects: 60
Study 6446445 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (4000 mg)
Number of subjects: 60
Study 6446445 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (150 mg)
Number of subjects: 60
Study 30193565 — intervention group
Group type: EXPERIMENTAL
Intervention: Short message systems in addition to face to face education
Number of subjects: 100
Study 30193565 — intervention group
Group type: COMPARATOR
Intervention: Face to face education
Number of subjects: 100
Study 31837648 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS + Nintendo Switch game
Number of subjects: 30
Study 31837648 — intervention group
Group type: COMPARATOR
Intervention: sham tDCS
Number of subjects: 30
Study 31837648 — intervention group
Group type: COMPARATOR
Intervention: tDCS only (group 3)
Number of subjects: 30
Study 27808418 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (300 mg)
Number of subjects: 15
Study 27808418 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (3,000 mg)
Number of subjects: 15
Study 27808418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 26329661 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (group K)
Number of subjects: 200
Study 26329661 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (group T)
Number of subjects: 200
Study 26329661 — intervention group
Group type: COMPARATOR
Intervention: Both groups (K and T)
Number of subjects: 200
Study 23846175 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine postprocedural chest X‐ray (group 1)
Number of subjects: 100
Study 23846175 — intervention group
Group type: COMPARATOR
Intervention: Chest X‐ray only when clinically indicated (group 2)
Number of subjects: 100
Study 21742103 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (T)
Number of subjects: 209
Study 21742103 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (C)
Number of subjects: 209
Study 19831165 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.0% arginine toothpaste
Number of subjects: 125
Study 19831165 — intervention group
Group type: COMPARATOR
Intervention: Benchmark desensitizing toothpaste
Number of subjects: 125
Study 19831165 — intervention group
Group type: COMPARATOR
Intervention: Control toothpaste
Number of subjects: 125
Study 16613932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensite NavX
Number of subjects: 145
Study 16613932 — intervention group
Group type: EXPERIMENTAL
Intervention: Carto
Number of subjects: 145
Study 16613932 — intervention group
Group type: COMPARATOR
Intervention: Conventional mapping
Number of subjects: 145
Study 16613932 — intervention group
Group type: EXPERIMENTAL
Intervention: NavX
Number of subjects: 145
Study 15105061 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing (15 microg ethinylestradiol and 120 microg etonogestrel daily)
Number of subjects: 83
Study 15105061 — intervention group
Group type: COMPARATOR
Intervention: Combined oral contraceptive (30 microg ethinylestradiol and 150 microg levonorgestrel)
Number of subjects: 83
Study 11277450 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective rehearsal and cognitive inhibition in children and adults
Number of subjects: 0
Study 11277450 — intervention group
Group type: COMPARATOR
Intervention: Cued recall and recognition tests
Number of subjects: 0
Study 9594355 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyconutritional supplement (saccharides) for six weeks
Number of subjects: 17
Study 9594355 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytonutritional supplement (added after three weeks)
Number of subjects: 17
Study 9594355 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (prescribed doses maintained or reduced by half)
Number of subjects: 17
Study 8964329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone 500 mg Q8 hours for 10 doses followed by oral prednisone for two weeks and tapering doses thereafter
Number of subjects: 16
Study 8964329 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone one mg per kilogram of body weight for two weeks followed by tapering doses
Number of subjects: 16
Study 2687306 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized night waking programme involving organized bedtime routines, procedures for settling the child, and handling of crying, calling out, and getting out of bed.
Number of subjects: 0
Study 2687306 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information only
Number of subjects: 0
Study 2687306 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study 4140005 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate 200 mug daily
Number of subjects: 25
Study 4140005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31785587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXT; 6 IU, 12 IU, 24 IU)
Number of subjects: 90
Study 31785587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXT)
Number of subjects: 90
Study 30699178 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacc‐4x booster immunizations (1.2mg) with GM‐CSF (60μg) as a local adjuvant
Number of subjects: 33
Study 28679021 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of oxytocin (10 IU)
Number of subjects: 33
Study 28679021 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal administration of oxytocin (100 or 400 IU)
Number of subjects: 33
Study 28679021 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal administration of oxytocin
Number of subjects: 33
Study 26355232 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept in combination with mFOLFOX6
Number of subjects: 96
Study 26355232 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 96
Study 23002282 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with pertuzumab (arm A, n=74)
Number of subjects: 149
Study 23002282 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (arm B, n=75)
Number of subjects: 149
Study 22099466 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLD activity in the VTA
Number of subjects: 0
Study 22099466 — intervention group
Group type: EXPERIMENTAL
Intervention: BOLD activity in ventral striatum (VS)
Number of subjects: 0
Study 19565733 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm needle moxibustion
Number of subjects: 125
Study 19565733 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 125
Study 19565733 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (Prostat Tablets)
Number of subjects: 125
Study 17380850 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg
Number of subjects: 49
Study 17380850 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 49
Study 15382805 — intervention group
Group type: EXPERIMENTAL
Intervention: ICEX sockets
Number of subjects: 27
Study 15382805 — intervention group
Group type: COMPARATOR
Intervention: PTB sockets
Number of subjects: 27
Study 11421877 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.d. plus amoxicillin 1 g b.d. and tinidazole 500 mg b.d. (RAT group)
Number of subjects: 285
Study 11421877 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.d. plus amoxicillin 1 g b.d. and clarythromycin 500 mg b.d. (RAC group)
Number of subjects: 285
Study 11421877 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.d. plus clarythromycin 500 mg b.d. and tinidazole 500 mg b.d. (RCT group)
Number of subjects: 285
Study 11421877 — intervention group
Group type: COMPARATOR
Intervention: Maastricht triple therapy
Number of subjects: 285
Study 9431863 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (1 micromol/l, 15 min) after hypoxia-reoxygenation
Number of subjects: 28
Study 9431863 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (0.1 micromol/l, n=5) pretreatment (15 min before hypoxia)
Number of subjects: 28
Study 9431863 — intervention group
Group type: EXPERIMENTAL
Intervention: High stimulation rate (400 ms CL) during hypoxia
Number of subjects: 28
Study 9431863 — intervention group
Group type: EXPERIMENTAL
Intervention: Low stimulation rate (1600 ms CL) during hypoxia
Number of subjects: 28
Study 9431863 — intervention group
Group type: COMPARATOR
Intervention: Time-related controls (Tyrode's solution for 225 min at cycle length (CL) 1600 ms and no dobutamine)
Number of subjects: 28
Study 8480740 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (15 mg/kg)
Number of subjects: 0
Study 8480740 — intervention group
Group type: COMPARATOR
Intervention: Skim milk (equimolar phenylalanine to aspartame)
Number of subjects: 0
Study 8480740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3613408 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein diet
Number of subjects: 13
Study 3613408 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet
Number of subjects: 13
Study 31599994 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 19
Study 31599994 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 19
Study 28483745 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app for pelvic floor muscle training (PFMT), prescribed 3 times daily for 3 months.
Number of subjects: 123
Study 28483745 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group).
Number of subjects: 123
Study 26250359 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 4113